Use of prophylactic antibiotics

Lawrence Wolff

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Infection is the major cause of morbidity and mortality in children receiving anticancer therapy. Children who have severe neutropenia (neutrophil count less than 100/mm3 for longer than 2 weeks should receive oral antibiotic prophylaxis. At present, trimethoprim sulfamethoxazole in combination with either nystatin or amphotericin B is the best regimen for reducing the incidence of serious infections. Trimethoprim sulfamethoxazole is very effective in the prevention of Pneumocystis carinii pneumonitis. Clinicans will have to balance the advantages and disadvantages of prophylaxis in patients who are at risk for P. Carinii pneumonitis.

Original languageEnglish (US)
Pages (from-to)267-276
Number of pages10
JournalJournal of Pediatric Hematology/Oncology
Volume6
Issue number3
StatePublished - 1984

Fingerprint

Sulfamethoxazole Drug Combination Trimethoprim
Pneumonia
Anti-Bacterial Agents
Pneumocystis carinii
Nystatin
Child Mortality
Antibiotic Prophylaxis
Amphotericin B
Infection
Neutropenia
Neutrophils
Morbidity
Incidence
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Use of prophylactic antibiotics. / Wolff, Lawrence.

In: Journal of Pediatric Hematology/Oncology, Vol. 6, No. 3, 1984, p. 267-276.

Research output: Contribution to journalArticle

Wolff, L 1984, 'Use of prophylactic antibiotics', Journal of Pediatric Hematology/Oncology, vol. 6, no. 3, pp. 267-276.
Wolff, Lawrence. / Use of prophylactic antibiotics. In: Journal of Pediatric Hematology/Oncology. 1984 ; Vol. 6, No. 3. pp. 267-276.
@article{094fb9a2b25943d8af6583d622b902e9,
title = "Use of prophylactic antibiotics",
abstract = "Infection is the major cause of morbidity and mortality in children receiving anticancer therapy. Children who have severe neutropenia (neutrophil count less than 100/mm3 for longer than 2 weeks should receive oral antibiotic prophylaxis. At present, trimethoprim sulfamethoxazole in combination with either nystatin or amphotericin B is the best regimen for reducing the incidence of serious infections. Trimethoprim sulfamethoxazole is very effective in the prevention of Pneumocystis carinii pneumonitis. Clinicans will have to balance the advantages and disadvantages of prophylaxis in patients who are at risk for P. Carinii pneumonitis.",
author = "Lawrence Wolff",
year = "1984",
language = "English (US)",
volume = "6",
pages = "267--276",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Use of prophylactic antibiotics

AU - Wolff, Lawrence

PY - 1984

Y1 - 1984

N2 - Infection is the major cause of morbidity and mortality in children receiving anticancer therapy. Children who have severe neutropenia (neutrophil count less than 100/mm3 for longer than 2 weeks should receive oral antibiotic prophylaxis. At present, trimethoprim sulfamethoxazole in combination with either nystatin or amphotericin B is the best regimen for reducing the incidence of serious infections. Trimethoprim sulfamethoxazole is very effective in the prevention of Pneumocystis carinii pneumonitis. Clinicans will have to balance the advantages and disadvantages of prophylaxis in patients who are at risk for P. Carinii pneumonitis.

AB - Infection is the major cause of morbidity and mortality in children receiving anticancer therapy. Children who have severe neutropenia (neutrophil count less than 100/mm3 for longer than 2 weeks should receive oral antibiotic prophylaxis. At present, trimethoprim sulfamethoxazole in combination with either nystatin or amphotericin B is the best regimen for reducing the incidence of serious infections. Trimethoprim sulfamethoxazole is very effective in the prevention of Pneumocystis carinii pneumonitis. Clinicans will have to balance the advantages and disadvantages of prophylaxis in patients who are at risk for P. Carinii pneumonitis.

UR - http://www.scopus.com/inward/record.url?scp=84938027463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938027463&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 267

EP - 276

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 3

ER -